เอกสารอ้างอิง
[1]. ป่วน สิทธิพินิจธรรม, วัณณศรี สินธุภัค, นุชา เนียมประดิษฐ์ และคณะ. Clinical Practice Guideline: Superficial Fungal Infection. Available form: https://www.iod.go.th/clinical-practice-guideline-for-superficialfungalinfection-2011. Accessed November 19, 2021.
[2]. Goldstein AO, Bhatia N. Onychomycosis: Epidemiology, clinical features, and diagnosis. In: Post TW, ed. UpToDate, Waltham, MA. (Accessed on November 23, 2021.)
[3]. Leung AKC, Lam JM, Leong KF, Hon KL, Barankin B, Leung AAM, Wong AHC. Onychomycosis: An Updated Review. Recent Pat Inflamm Allergy Drug Discov. 2020;14(1):32-45.
[4]. Elewski BE, Hay RJ. Update on the management of onychomycosis: highlights of the Third Annual International Summit on Cutaneous Antifungal Therapy. Clin Infect Dis. 1996 Aug;23(2):305-13.
[5]. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. Available form: http://www.fda.gov/Drugs/DrugSafety/ucm362415.
htm. Accessed November 19, 2021.
[6]. Kao WY, Su CW, Huang YS, Chou YC, Chen YC, Chung WH, Hou MC, Lin HC, Lee FY, Wu JC. Risk of oral antifungal agent-induced liver injury in Taiwanese. Br J Clin Pharmacol. 2014 Jan;77(1):180-9.
[7]. García Rodríguez LA, Duque A, Castellsague J, Pérez-Gutthann S, Stricker BH. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol. 1999 Dec;48(6):847-52.
[8]. สำนักงานคณะกรรมการอาหารและยา. การจำกัดข้อบ่งใช้ยา ketoconazole ชนิดรับประทาน. Medication and health product bulletin. 2015(October-December);18(4):97-100.
[9]. National Drug Information. Ketoconazole [Internet]. [cited 2021 November 16]. Available form: http://ndi.fda.moph.go.th/drug_national_detail/index/6759.
[10]. Haneke E, Tausch I, Bräutigam M, Weidinger G, Welzel D. Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. LAGOS III Study Group. J Am Acad Dermatol. 1995 Jan;32(1):72-7.
[11]. Gupta AK, De Doncker P, Scher RK, Haneke E, Daniel CR 3rd, André J, Baran R. Itraconazole for the treatment of onychomycosis. Int J Dermatol. 1998 Apr;37(4):303-8. doi: 10.1046/j.1365-4362.1998.00360.x. PMID: 9585906.
[12]. Mishra M, Panda P, Tripathy S, Sengupta S, Mishra K. An open randomized comparative study of oral itraconazole pulse and terbinafine pulse in the treatment of onychomycosis. Indian J Dermatol Venereol Leprol. 2005 Jul-Aug;71(4):262-6.
[13]. Arca E, Taştan HB, Akar A, Kurumlu Z, Gür AR. An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. J Dermatolog Treat. 2002 Mar;13(1):3-9.
[14] Shinkai K, Fox LP. Dermatologic Disorders. In: Papadakis MA, McPhee SJ, ed. Current Medical Diagnosis & Treatment. 59th ed. New York: McGraw-Hill. 2020:106-176.